



Newron announces AGM 2023 results

Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda of the AGM 2023 held today.

The agenda consisted of the approval of the balance sheet as at December 31, 2022, the appointment of the members of the Board of Directors for the financial years 2023-2025, and the determination of the remuneration of the Board of Directors.

Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: *“We thank all our shareholders for their ongoing and longstanding support and trust”. He added: “On behalf of the Board and the Management Team, I also thank J. Donald (Don) deBethizy for his many valuable contributions to our company and his innovative thinking as member of the Board of Directors since 2014, most notably as Chairman of the R&D committee. At the same time, we welcome Gillian Dines as newly elected Board member and Chairwoman of the R&D committee. We are looking forward to working with her and are convinced that her profound R&D knowledge and entrepreneurial personality will be an asset to Newron”.*

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information, please contact:

Newron

Stefan Weber – CEO, +39 02 6103 46 26, pr@newron.com

UK/Europe

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting, +44 20 3727 1000
SCnewron@fticonsulting.com

Switzerland

Valentin Handschin, IRF, +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe

Anne Hennecke / Caroline Bergmann, MC Services, +49 211 52925222, newron@mc-services.eu

USA

Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, psagan@lavoiehealthscience.com